2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 936

IL-1 Receptor Antagonist Maintains Intestinal Microbial Homeostasis to Prevent Overt Toll-like Receptor 4-Dependent Intestinal Th17 Differentiation and Autoimmune Arthritis
Abstract Number: 1136

IL-1β-Induced Stress Granules Sequester COX-2 mRNA and Regulates Its Expression in Human OA Chondrocytes
Abstract Number: 2814

IL-10 May Mitigate Cardiovascular Risk in Psoriatic Arthritis Via an Anti-Atherosclerotic Effect on Cellular Cholesterol Transport
Abstract Number: 3043

IL-17 Expression By Lymphocytes Is Higher in Behcet’s Disease Compared to Takayasu Arteritis
Abstract Number: 2813

IL-17 Induces Skin Inflammation Independently of IL-23R+ T Cells and Is Protected By Conditional Deletion of Wdfy3 in Neutrophils
Abstract Number: 1932

IL-17A-Low CCR6+ Th Cell Populations of Patients with Rheumatoid Arthritis Are Pathogenic, Multidrug Resistant and Associated with DMARD and Glucocorticoid Treatment Response
Abstract Number: 3020

IL-21 Abrogates CD4+CD25+FOXP3+ Treg Differentiation in Part By Suppressing Treg GATA-3 Expression in SLE
Abstract Number: 1377

IL-22 Drives the Proliferation and Differentiation of Human Bone Marrow Mesenchymal Stem Cells (MSCs); A Novel Pathway That May Contribute to Aberrant New Bone Formation in Human Spa and Beyond
Abstract Number: 544

IL-6 May Have an Important Role in the Resistance to Anti-TNF Therapies of Human T-Lymphotropic Virus Type 1 (HTLV-1) Positive Rheumatoid Arthritis (RA) Patients; HTLV-1 Infected Cells Activate the Inflammatory Responses of RA Synovial Fibroblasts
Abstract Number: 2761

IL-6R Blockade with Sarilumab Plus Methotrexate Results in Changes in Clinical and Laboratory Parameters Associated with Chronic Inflammation in Patients with Moderate-to-Severe RA in a Phase 3 Study
Abstract Number: 3201

IL-7 Drives Cytokine Secretion of IL-7Rabright CCR9-Expressing T-Follicular Helper-like Cells: Potential New Axis in Lymphoid Neogenesis in Salivary Glands of Primary Sjogren s Syndrome Patients
Abstract Number: 3156

IL17 Promotes Development of Autoreactive Early Stage B Cells in Distinct Regions of the Spleen Follicle
Abstract Number: 2793

IL35 Serum Level Is Decreased in Patients with Primary Sjogren Syndrome, Essentially in Patients with the More Active Disease Data from the French Prospective Assess Cohort
Abstract Number: 1162

IL37 Reduces Pro-Inflammatory Cytokine and Catabolic Enzyme Production in Human Chondrocytes: A Protective Role in Osteoarthritis?
Abstract Number: 1092

Illicit Drug Use in US Adults with Chronic Low Back Pain: Nhanes 2009-2010

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].